Home
Resources
Publications
Effectiveness of Imazodan for Treatment of Chronic Congestive Heart Failure. The Imazodan Research Group

Effectiveness of Imazodan for Treatment of Chronic Congestive Heart Failure. The Imazodan Research Group

A D Goldberg, J Nicklas, S Goldstein

Am J Cardiol. 1991 Sep 1;68(6):631-6.

PMID: 1715125

Abstract:

A 12-week, multicenter, double-blind, randomized, placebo-controlled trial of imazodan, a type III phosphodiesterase inhibitor, was conducted in 147 patients with congestive heart failure to determine clinical efficacy and safety. Patients were randomized to placebo or 2, 5 or 10 mg of imazodan administered twice daily. Patients were maintained on their standard therapy including diuretics, digoxin and an angiotensin-converting enzyme inhibitor. The mean ejection fraction was 23 +/- 10%. Exercise time increased from baseline in all 4 groups. There was no significant difference observed between the placebo group and any of the treated groups with regard to exercise time, ejection fraction, frequency of ventricular premature complexes or ventricular tachycardia. When analyzed by intent to treat, the placebo mortality was 7% (3 of 44) and the imazodan mortality was 8% (8 of 103) (p = not significant). This study failed to demonstrate that imazodan provided any benefit in exercise performance when compared with placebo.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP84243583	Imazodan		84243-58-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: